Compound 46
Identifiers
- Canonical SMILES:
Brc1ccc(cc1)[C@H]1Oc2ccccc2C2=C1[C@@H](c1ccc(Br)cc1)n1ncnc1N2
- InChi:
InChI=1S/C24H16Br2N4O/c25-16-9-5-14(6-10-16)22-20-21(29-24-27-13-28-30(22)24)18-3-1-2-4-19(18)31-23(20)15-7-11-17(26)12-8-15/h1-13,22-23H,(H,27,28,29)/t22-,23-/m1/s1
- InChiKey:
HNNGTASVWGJHBY-DHIUTWEWSA-N
External links
1874292 |
CHEMBL583427 |
4698299 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
MDM2-Like / P53 | 5.41 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 533.97 g/mol | |||
HBA | 5 | |||
HBD | 1 | |||
HBA + HBD | 6 | |||
AlogP | 5.87 | |||
TPSA | 51.97 | |||
RB | 2 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4299 | BMS-394136 | DB12067 | |
0.3779 | GDC-0927 | DB14934 | |
0.3483 | LY-2881835 | DB15046 | |
0.3406 | Rocaglamide | DB15495 | |
0.3392 | Iclaprim | DB06358 | |
0.3392 | (S)-iclaprim | DB07938 | |
0.3392 | 5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine | DB08741 | |
0.3375 | Parsaclisib | DB14867 | |
0.3374 | Cannabichromene | DB14735 | |
0.3374 | MK-1775 | DB11740 | |
0.3370 | Didesmethylrocaglamide | DB15496 | |
0.3364 | (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium | DB02673 | |
0.3345 | Galicaftor | DB14894 | |
0.3300 | Posaconazole | DB01263 | |
0.3297 | Monastrol | DB04331 |